MedTrace Logo

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

NCT06477159 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-22

No results posted yet for this study

Summary

This study aims to evaluate if a 6-month course of pancrelipase (CREON) treatment improves symptoms of exocrine pancreatic insufficiency (EPI) after an attack of acute pancreatitis. Diagnosis of EPI is measured by a fecal elastase value of \<200, and patients must have a qualifying symptom burden based on the EPI symptom tracker survey. Blood and stool will be analyzed as part of this study, and other surveys of health status will be used to track improvement of symptoms.

Conditions

  • Exocrine Pancreatic Insufficiency

Interventions

DRUG

Pancrelipase Capsules

Treatment with Pancreatic Enzyme Replacement Therapy

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • University of Illinois Chicago

    collaborator UNKNOWN

  • University of Southern California

    collaborator OTHER

  • New York University

    collaborator OTHER

  • AbbVie

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477159 on ClinicalTrials.gov